RFC
LRMR icon

Russell Frank Company’s Larimar Therapeutics LRMR Stock Holding History

Russell Frank Company’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,680
Closed -$798K – 3061
2015
Q1 		$798K Buy
+1,680
New +$798K ﹤0.01% 2251

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Russell Frank Company's LRMR Position: Q2 2015 in Review

Russell Frank Company sold out of Larimar Therapeutics (LRMR) in Q2 2015, closing a stake of 1,680 shares — an estimated $798K sold.

Russell Frank Company first reported a position in LRMR in Q1 2015 and held it in 1 quarter. The position peaked at $798K in Q1 2015. 89 funds tracked by Wall St. Rank hold LRMR as of Q2 2015.

  • Russell Frank Company reported no remaining Larimar Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Russell Frank Company sold 1,680 Larimar Therapeutics shares in Q2 2015, an estimated $798K.
  • Russell Frank Company first reported a position in Larimar Therapeutics in Q1 2015 and held it in 1 quarter.
  • Russell Frank Company's Larimar Therapeutics position peaked at $798K in Q1 2015.
  • 89 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2015.

Based on Russell Frank Company's 13F filing for Q2 2015, filed 13 Aug 2015.